**Company Registration Number: 07493363 Charity Number: 1140193** 

## **CRIS CANCER FOUNDATION** 

**A COMPANY LIMITED BY GUARANTEE (CHARITY No. 1140193)** 

**REPORT AND FINANCIAL STATEMENTS** 

**FOR THE YEAR ENDED 31 DECEMBER 2025** 


RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



**CRIS CANCER FOUNDATION** 

## **A COMPANY LIMITED BY GUARANTEE (CHARITY NO. 1140193)** 

## **ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Index**|**Page**|
|---|---|
|Report of the trustees|1 - 7|
|Report of the auditors|8 - 10|
|Statement of financial activities|11|
|Balance sheet|12|
|Cash flow statement|13|
|Notes forming part of the financial statements|14 - 23|



RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

The trustees, who are also directors of the charitable company for the purposes of company law, present their report along with the financial statements for the year ended 31 December 2025. 

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102). 

## **Objectives and activities** 

The objects of CRIS Cancer Foundation (CRIS) are to protect and promote the health of the public through supporting research into the nature, causes, diagnosis, prevention, treatment and cure of all forms of cancer, including the development of research findings into practical applications for the prevention, treatment and cure of cancer and to provide information and raise public understanding of such matters. 

## **Public benefit** 

The directors have complied with section 17(5) of the 2011 Charities Act, having due regard for the Charity ��������������������������������������������������������������������������������������� 

## **Achievements and performance** 

2025 was another successful year for CRIS Cancer Foundation. Thanks to the continued generosity of our donors, corporate partners, volunteers and supporters, the charity achieved its highest ever level of income, allowing us to make our largest annual investment in cancer research. 

During the year, CRIS Cancer Foundation strengthened its corporate fundraising programme and successfully launched its first Spring Gala, broadening its fundraising activities while continuing to grow support for its mission. 

Total incoming resources reached £3,825,447, an increase of approximately 12% compared with 2024 (£3,407,641). Of this, £2,541,743 was invested directly in research projects, representing a 22% increase on the £2,082,585 invested in 2024 and the highest annual research investment in the charity's history. For every £1 raised, 83.1p was invested directly in cancer research (2024: 84.0p). The small reduction compared with the previous year reflects the charity's decision to invest more in fundraising activities, particularly the expansion of the Corporate Partnerships programme and the launch of the Spring Gala. These investments are expected to strengthen fundraising capacity in the coming years. Administrative costs remained low at just 3.2% of total income, while every £1 invested in fundraising generated £7.34 of income. 

The charity's principal fundraising activities during the year were as follows. 

## Annual Gala 

The 15th CRIS Cancer Foundation Annual Gala was held on 15 November 2025 at the Natural History Museum in London. The event brought together several hundred supporters, researchers, corporate partners and friends of CRIS Cancer Foundation and raised £2,772,478 (2024: £2,807,184). 

The evening opened with a welcome from CRIS Cancer Foundation co-founder Lola Manterola, while Professor Paul Workman was recognised for his outstanding contribution to cancer research. Guests also heard a moving testimony from Delphine Heenen, Managing Director of KickCancer and co-founder of the Fight Kids Cancer consortium, highlighting the importance of continued investment in paediatric cancer research. 

The evening concluded with a coordinated LED bracelet display, shared simultaneously with guests attending the CRIS Cancer Foundation Gala in Paris, symbolising cancer survival rates and the international collaboration behind our mission. 

1 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

The Gala was generously supported by R.J. O'Brien (a StoneX Company), Tradeweb and Abadía Retuerta. 

## Corporate Partnerships 

Corporate fundraising continued to perform strongly during 2025, reaching £364,745, an increase of 165% compared with the previous year. 

This growth reflects the continued support of many companies that chose to support CRIS Cancer Foundation during the year through corporate donations, sponsorship of fundraising events or participation in our activities. These included Goldman Sachs, General Atlantic, VISA, D'Angelin & Co, the Spanish Chamber of Commerce and Quantum Pacific. We were also delighted to welcome a number of new corporate supporters in 2025, including UBS, Apple, Bank of America, Citigroup, BNP Paribas, TP ICAP, Taula Capital and JB Drax Honoré. 

We are extremely grateful for the generosity and commitment of all our corporate supporters, whose contributions help CRIS Cancer Foundation continue funding world-class cancer research. 

## Spring Gala 

In May 2025, CRIS Cancer Foundation held its first Spring Gala at One Marylebone in London. The event offered a more intimate opportunity for donors, researchers, trustees, ambassadors, volunteers and patients to come together and celebrate the impact of cancer research. Guests heard the personal story of ovarian cancer survivor Sophie Haig-Thomas, whose testimony illustrated the difference that research can make to patients and their families. 

The inaugural Spring Gala raised £233,239 and has become an important addition to the charity's annual fundraising programme. 

## Other Fundraising Activities 

The charity's wider fundraising programme continued throughout the year. 

The Royal Parks Half Marathon brought together 48 runners who collectively raised approximately £30,000 in support of CRIS Cancer Foundation. 

The Run for Fight Kids Cancer in Madrid generated £47,897 more than in the previous year, reflecting increased participation and continued support for the campaign. 

My Super CRIS Challenge and World Cancer Day continued to engage supporters throughout 2025. Although income from these activities was lower than in the previous year, they remain important awareness and community fundraising initiatives for CRIS Cancer Foundation. 

## **Investment Income** 

Income from bank interest totalled £34,847 (2024: £31,184), reflecting prudent management of the charity's cash balances. 

## **Research Investment and Impact** 

In 2025, CRIS Cancer Foundation invested a record £2,541,743 in cancer research, supporting leading research institutions across the United Kingdom and, through the Fight Kids Cancer consortium, across Europe. 

2 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

The charity's principal research investments included: ������������������������������������������������������������������������������������������������ research commitment. Together with KickCancer, Imagine for Margo, Fondation Kriibskrank Kanner and �������������������������������������������������������������to 46 research projects across 20 European countries, supporting both translational research and early-stage clinical trials in paediatric oncology. 

����������������������������������������������������������������������������������������������������� multidisciplinary research into cellular immunotherapies and early-phase clinical trials combining immunomodulatory drugs with precision monitoring. 

����������-T Therapy for Childhood Leukaemia, Great Ormond Street Hospital and UCL (£214,000). CRIS Cancer Foundation continued supporting Professor Persis Amrolia's programme developing dualtarget CAR-T therapies for children with relapsed or treatment-resistant leukaemia. 

���������������������������������������������������������������������������������������������� development of an innovative therapeutic vaccine for lung cancer. 

�������������������������������������������������������������������-career researchers including Dr Casmir Turnquist, developing rapid diagnostic tools for childhood and young adult cancers, and Dr Rebecca Ling, investigating the developmental origins of infant acute myeloid leukaemia associated with KMT2A alterations. 

�������������������������������������������������������������������������������������������������� supporting Dr Chris Jones' internationally recognised research into diffuse midline glioma, helping to build one of the world's leading catalogues of genetic alterations in childhood brain tumours. 

������������������������������������������������������������������������������������������������������������ improve understanding of sarcoma biology and identify potential new treatment approaches for these rare cancers. 

��������������������������������������������������������������������������������������������������������� is investigating how the stress-response protein IRE1 contributes to treatment resistance in prostate cancer and whether regulating its activity could improve long-term treatment responses. 

���������������������������������������������������������������������������������������������������� £220,000). This new programme, led by Sir Mel Greaves and Dr Marcela Braga Mansur, is investigating how TP53 loss accelerates the evolution of treatment-resistant leukaemia cells, with the long-term objective of preventing resistance before it develops. 

CRIS Cancer Foundation also continued supporting a number of additional fellowships, project extensions and collaborative research programmes, including the Institute of Cancer Research Research Fellowship, the Multiple Myeloma programme led by Dr Charlotte Pawlyn, the extension of Dr Astero Klampatsa's immunotherapy project, and research collaborations with CRIS France and Fundación CRIS Contra el Cáncer. 

These investments demonstrate the strong relationships that CRIS Cancer Foundation has developed with leading research institutions including the Institute of Cancer Research, the University of Oxford, Great Ormond Street Hospital, Cancer Research UK and the Fight Kids Cancer consortium. 

3 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

Every research project funded by CRIS Cancer Foundation is independently reviewed and recommended by the International Scientific Committee, ensuring that charitable funds are invested in research with the greatest scientific quality and the strongest potential to improve outcomes for patients. 

The Trustees remain committed to supporting world-class cancer research while continuing to strengthen the charity's relationships with leading research institutions, corporate partners and major donors. This approach will help ensure that CRIS Cancer Foundation can continue increasing its investment in innovative research in the years ahead. 

Finally, none of this would have been possible without the generosity of our donors, volunteers, researchers, corporate partners and Trustees. Their continued commitment enables CRIS Cancer Foundation to invest in research that brings us closer to better treatments and, ultimately, to cures for cancer. 

## **Financial review** 

The results for the period are as set out on page 11 and show that the charity achieved a very successful fundraising period in 2025. Total income for the year ended 31 December 2025 amounted to £3,825,447 (2024: £3,407,641) of which £2,772,478 (2024: £2,807,184) was raised from events. After fundraising costs of £386,543 (2024: £295,595), the net funds raised from events for the period were £2,385,935 (2024: £2,511,589). 

During the period CRIS made total donations of £2,541,743 (2024: £2,082,585) including to the Institute of Cancer Research (ICR), Oxford, CRUK and Fight Kids Cancer. Overall, total surplus was £638,524 (2024: £780,509). 

At the financial period end, together with reserves brought forward of £3,761,989 (2024: £2,981,480), the total funds, all of which are unrestricted, available for carry forward amounted to £4,400,513 (2024: £3,761,989). 

## **Investment policy and performance** 

���������������������������������������������������������� and the current policy is to invest short term deposits ���������������������������� 

## **Reserves policy and going concern** 

��������������������������������������������������������������������������������������������������������������������� to continue. The amount of funds required to operate the charity is not significant at an estimated amount of £167,000 per annum. The trustees do not charge the charity for the services they provide and the events that are held are invariably self-funding events. CRIS is accordingly in an enviable position as the risk of it not being able to operate as a going concern due to lack of funds is considered to be remote. 

## **Structure, governance and management** 

CRIS Cancer Foundation (CRIS) was incorporated on 14 January 2011 as a charitable company which is limited by guarantee with no share capital and governed by its Articles of Association. CRIS was registered as a charity with the Charity Commission for England and Wales on 2 February 2011.  The liability of each member in the event of winding up is limited to a maximum of £1. 

In accordance with the governing document, there shall be not less than three directors at any one time. The directors, who are also the charity trustees, are normally elected by the members of the company in a general meeting. 

4 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

Trustees are appointed on the basis of specific skills and knowledge to enable them to make a contribution to the management of the charity. In order for trustees to undertake such responsibilities, appropriate Charity Commission publications, in particula����������������������������������������������������������������������� to each trustee as part of their induction process. 

## **Risk management** 

The trustees have reviewed the major and financial risks that impact on the work of the charity and undertake reviews of risk management on a continuing basis. The systems that have been established enable the trustees to review and take necessary steps to lessen these risks. 

## **Future development** 

The trustees remain committed to supporting world-class cancer research while ensuring the long-term financial sustainability of the charity. 

During 2026, the trustees ������������������������������������������������������������������������������������ new corporate partnerships, expanding community fundraising initiatives and building on the success of the Annual Gala. The trustees �������������������������������������������������������������������������������� explore opportunities to increase income through charitable trusts, foundations and grant-making ������������������������������������������������������������������������������� long-term resilience. 

The trustees also plan to undertake a strategic review of the UK charitable sector to identify opportunities for future growth, better understand the evolving fundraising landscape and ensure that CRIS Cancer Foundation continues to adopt the most effective approaches to maximise its impact. 

����������������������������������������������������������������������������������������������������������� This initiative will invite leading UK research institutions to submit proposals through an independent scientific review process, ensuring that future research funding continues to support projects of the highest scientific quality and greatest potential benefit to patients. 

The trustees ��������������������������������������������������������������������������������������������������� commitments remain sustainable while maximising the proportion of funds invested directly in research. 

Above all, the trustees remain committed to ensuring that CRIS Cancer Foundation delivers the greatest possible benefit to patients and their families. While scientific excellence will always remain at the heart of �������������������������������������trustees believe that research should ultimately lead to better treatments reaching patients as quickly as possible. Supporting research that has the potential to accelerate the translation of scientific discoveries into clinical practice will therefore remain a central priority for the charity in the years ahead. 

5 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Reference and administrative information** 

|**Directors/Trustees**|Marta Brime - Chairman|
|---|---|
||Nicola Louise Amoroso|
||Maria Dolores Manterola (aka Lola Manterola)|
||Fernando Delgado-Nevares|
||Geraldine Creaturo|
||Diego Megia|
||Alvaro Portanet|
||Snigdha Singh|
||Josefa Diaz Mercado|
||Christopher Ciauri (resigned on 27 January 2026)|
||Ana De Paz Bonachera|
|**Treasurer**|Ana De Paz|
|**Company number**|07493363|
|**Registered charity number**|1140193|
|**Registered office**|Quadrant House - Floor 6, 4 Thomas More Square, London E1W|
||1YW|
|**Place of business**|Second floor office, 3A Harrington Road, South Kensington,|
||London SW7 3ES|
|**Auditors**|UHY Hacker Young, Quadrant House, 4 Thomas More Square,|
||London E1W 1YW|
|**Bankers**|Virgin Money, 177 Bothwell Street, Glasgow G2 7ER|
|**Solicitors**|Bates Wells & Braithwaite London LLP|
||2-6 Cannon Street, London EC4M 6YH|



6 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Responsibilities of the Board** 

The Trustees who are also the directors of the Foundation for the purposes of company law are responsible ������������������������������������������������������������������������������������������������������������� Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Foundation and the incoming resources and application of resources, including the income and expenditure, of the Foundation for that period. 

In preparing these financial statements, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charities SORP; 

- make judgements and estimates that are reasonable and prudent; 

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Foundation will continue in business. 

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Foundation and enable the Trustees to ensure that the financial statements comply with the Companies Act 2006.  The Trustees are also responsible for safeguarding the assets of the Foundation and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006. 

## **By order of the Board:** 


���������� 

**Marta Brime � Trustee Secretary of Board of Trustees** 

> Date: `14/07/2026` 

7 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 




## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS AND TRUSTEES OF CRIS CANCER FOUNDATION FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Opinion** 

�������������������������������������������������������������������������������able Company�����������year ended 31 December 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting ��������������������������������������������������������������������������ting Standard applicable in the UK ��������������������������������������������������������������������������������� 

- In our opinion the financial statements: 

   - give a true and fair view of the state of the Charitable Company�������������������������������25 and of its incoming resources and application of resources, for the year then ended; 

   - have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

   - have been prepared in accordance with the requirements of the Companies Act 2006. 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charitable Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the ������������������������������������������������������������cal responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

������������������������������������������������������������������������������������������������������������� accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charitable Company�������������� continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

��������������������������������������������������������������������������������������������������������������� statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. 

8 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



UHY
UHY H•cknr Yo
Quèdi'anl House
4 ThcJrnas IAore SqJare
London Elw IYW
INDEPENDENT ALry)ITORS' REPORT TO THE MEI¥IBERS AND TRUSTEES OF CRIS CANCER
FOUNDATION FOR THE YEAR ENDED 31 DECEMBER 2025
Opinions on other matters preserAbed by tbe Comp*llles Att 2006
In our opinion. based on the work undertaken iu the course of our audii..
the infomiation given in the trustees. report for the fjnanciat year for wbi¢h the financial statements are
prepared is consisiettt with the financial statements: and
the trusttts, report ba5 prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the lighi of the knowledge and undeTStanth"n(p of the Chan"table Company and its environtDent obtsined in the
course of our audil we have noi identt.fied n)aterial missta*ments in the Trustees. Rqx)rt (whach incorporates the
directors. report).
We have nothing to report in respect of the followiDg tDatters ID r¢]ation towhich the Companies Act 2006 requires
us to report io you if. ill our qJinioD'.
adequate and proper accounting records bave not beeo k¢p( or returns ad* for our auth"t have not
been received frotD brdnche5 not visited by us,. or
the f￿ancIal statements are not in agrttmcot with the acc(M￿lIng records and rthms: or
certain disclosures of trustees, remunerati¢)n specifi￿J by law are noi th￿e. or
we have not receiv￿ all th¢ infornarion ond explanaiions we require for our audiL or
the trust¢es were not entitted io prepare the financial statements in accordance with the srnall comEwiies
r¢gim¢ and tJk¢ th￿lag¢ of the small Companies. exemptions in preparn￿ the strategic report.
Responslbllltles of trllsiees
As explained more ￿1]Y in the tsusiees. responsibilities ststement set out OD page 7. the In￿ee5, who are also the
diwtois of the charitable company for the purpose of Company law. are resEK)nsible for the prepaTation of th¢
finan¢ial ststements which give a and fair view. for such iniernal control as the trustres determEne is
necessary to ¢nabl¢ the preparnlioa of fJnan¢ial sra*ments thai are free from nJaterAal mi&staiemenL whether the
to fraud OF ern)r.
In preparing the fukancial sts￿ellts. the In￿te¢S are wttsible for assessing th¢ Clwitable Company's ability
io conunue as a concem. disclosu￿ as app￿.￿ble. matters related ts> going concern and using the going
concern basis of accounting unless the tsNstres eitbei iti*nd to liquidate the Charitable Company or to ￿8¢
operations. or have no realisti¢ aliernative but ￿ do so.
Auditor's responsibilitiu for the audit of the f￿4￿¢1￿1 statements
Our objectives are to obtain re&sonable &ssurdnce aFM)ui whether the fwn¢ial sthtrments as a wbole ate free from
￿￿tendI mi5Staternent, whether due to fraud or ern)r, and to i&sue on auditorfs re￿rt that includes our opinion.
ReasO[￿le assurance is a high level of ￿uranCe but isnot a guarantee thai an audit conduc¢ed in accordan¢e with
ISAS (UK) WLII always detect a rnaterial misstatetnent when it exists. Misstaternents can arise from fraud or error
and are cousidered rnaterial Ef. iudiYidu3lly or in the aggregate, they could re&qonably b¢ ewted ￿ jnfiue￿e the
economic decisions of useTS taken on the basts of these fuwKial statements.
Irregulartties, including fraud are instaa¢es ol ttjn-compliance with laws athl regulations. We de5t8n procedures
in line with our responsibilitie& oudined aiM)ve. to detect material mi&statemeDts in respe£t of irregularities,
including fraud. The exteni w wknch our procOlur￿ are capable of de*cw wlantie4 including frau4 is
d¢tsiled below.
B&fed on our understanding of the Charitsble Company and the industy in which tt optt*es. we identified that
the principal risks of non-compliance with laws and regulations ￿lated to the acts by the Chan"table Company,
which were contrary to applicable laws and regulaiions including fraurt and we ¢onsidertd the eKt¢nt to which
non-compliance might have a material effect on the financial sthicments. We also ￿nsIdered those law5 and
regulations that have a direct impact on the prepardtion of the financial Sts￿ments such as the Companies Art
2006. We evaluated management's incentiv&s and opportunities for fraudultnt manipulation of the financial
statements (including the risk of override of contro151 and determined thai tht principal risks were related to
¢ompletene&8 of iDCOrne.

UHY
UHY Hackor Young
Quaclrani Hou*
4 Thomas More Squaf&
London Elw IYW
DEPENDEf4T ALQ)ITORS' REPORT TO THE MEMBERS AND TRUSTEES OF CRIS CANCER
FOUNDATION FOR THE ITAR EYDED 31 DECEMBER 2025
Audit procedurts perfornied included: reiiew of the fIn￿la1 statemeui dixlosures io uJ)derlymg supporting
docurnentation, enquities of management and testing of journals and evajuaring whether there was evidence of
bias by the Trustees that represented a risk olmaterial missthtetDent due io fraud.
There are mhereni limitatiott8 iti the audit procedures described above and the further removed non-compliance
with laws and regulations is from the evet]ts and transactio￿ reflected in the f]llalltial statrments. the less likely
we would become aware of IL Also. the risk of not detrcting a material misstakmettt due to fraud is higher than
the risk of noi deie¢ting one resuliing from error. as fraud may involve delIbera￿ concea]ment by, for example.
forgery or intentiona] misrepre5enthts'ons. or through collusion.
A furtber description of our tESEX)Dsibilities for the audit of the financial statements is IcrAted on the Financial
Rewrting Coun¢d's websit ai.. www.frc.otE.uklauditorsrwLsibihties. This description forns part of our
audito¢s repon.
Use of our report
This report is made solely to the Charitsble Compan￿$ mejnbets, as a kndy. iti accotdante with Chapter 3 of Part
16 of the Companies Act 2006. (hlr audit WO￿ b&$ undertak¢n so thai we mighr stace to the Clwi"thble
Company's members th0￿ ￿￿tter$ we are required to stale to them in an auditors, rewjrt and for no other PUTPOSe.
To the fullest extent permitted by law. we do Dot accq)t or assume res￿)nsIb￿lty to any¢)ne other than the
Charitsble Company and its nlembers as a iK)dy. for our audit worL for thi5 retK)r( or for the opinions we have
fomked.
Rachel Chim (Senior Statutory Auditor).
UHY HAcker Young
Statutory Auditor
Quadrant House
4 Thotnas More Square
London Elw IYW
Date.. I
JbiLy .Jo*_
io

## **CRIS CANCER FOUNDATION** 

## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2025** 


**----- Start of picture text -----**<br>
|||||||||
|---|---|---|---|---|---|---|---|
|Unrestricted|Restricted|Total Unrestricted Restricted|Total|
|funds|funds|funds|funds|funds|funds|
|2025|2025|2025|2024|2024|2024|
|Notes|
|£|£|£|£|£|£|
|Incoming resources|
|Income from:|
|-Donations and legacies|3.1|1,018,122|- 1,018,122|569,273|-|569,273|
|-Other trading activities|3.2|2,772,478|- 2,772,478|2,807,184|- 2,807,184|
|-Investments|3.3|34,847|-|34,847|31,184|-|31,184|
|________|________ ________|________|________ ________|
|Total incoming resources|3,825,447|- 3,825,447|3,407,641|- 3,407,641|
|=======|======= =======|=======|======= =======|
|Expenditure on:|
|Raising funds:|
|Fundraising events|4|521,254|-|521,254|435,201|-|435,201|
|Charitable activities:|
|Donations made|4|2,665,669|- 2,665,669|2,191,931|- 2,191,931|
|________|________ ________|________|________ ________|
|Total|3,186,923|- 3,186,923|2,627,132|- 2,627,132|
|=======|======= =======|=======|======= =======|
|Net movement in funds|638,524|-|638,524|780,509|-|780,509|
|Reconciliation of funds|
|Total funds brought forward|3,761,989|- 3,761,989|2,981,480|- 2,981,480|
|________|________ ________|________|________ ________|
|Total funds carried forward|4,400,513|- 4,400,513|3,761,989|- 3,761,989|
|=======|======= =======|=======|======= =======|

**----- End of picture text -----**<br>


The results for the period are derived from continuing operations. 

There were no recognised gains or losses, other than those passing through the statement of financial activities. 

11 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **BALANCE SHEET AS AT 31 DECEMBER 2025** 

||||**31 December**||**31 December**|
|---|---|---|---|---|---|
||||**2025**||**2024**|
||**Notes**|**£**|**£**|**£**|**£**|
|**Fixed assets**||||||
|Tangible assets|5|-||-||
|Investments|6|199,998||199,998||
|||_______||_______||
||||199,998||199,998|
|**Current assets**||||||
|Debtors|7|517,024||816,338||
|Cash at bank||3,718,128||2,794,083||
|||_______||________||
|||4,235,152||3,610,421||
|**Creditors: Amounts falling due**||||||
|**within one year**|8|(34,637)||(48,430)||
|||_______||________||
|**Net current assets**|||4,200,515||3,561,991|
||||________||________|
|**Total assets less current liabilities**|||4,400,513||3,761,989|
||||________||________|
|Net assets|||4,400,513||3,761,989|
||||=======||=======|
|**Funds of the charity:**||||||
|Unrestricted funds|11||4,400,513||3,761,989|
|Restricted funds|||-||-|
||||________||________|
||||4,400,513||3,761,989|
||||=======||=======|



`14/07/2026` Approved by the Board and authorised for issue on ������� 


**����������** � 

## **Marta Brime - Director** 

**Company Number: 7493363** 

12 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **CASH FLOW STATEMENT AS AT 31 DECEMBER 2025** 

|||**31 Dec 2025**|**31 Dec 2024**|
|---|---|---|---|
||**Notes**|**£**|**£**|
|**Operating & investing activities**||||
|Receipts of interest||34,847|31,184|
|Receipts of other cash||4,057,813|3,131,075|
|Payment of charitable grants||(2,541,743)|(2,082,585)|
|Payment of expenses||(626,872)|(549,892)|
|Depreciation charge of tangible assets||-|3,437|
|Purchase of investments||-|-|
|||________|________|
|Increase in cash from operating & investing activities( A )||924,045|533,219|
|||________|________|
|Increase in cash|( B )|924,045|533,219|
|||=======|=======|
|**(A) Reconciliation of changes in resources to net cash**||||
|**inflow from operating & investing activities**||||
|||**2025**|**2024**|
|||**£**|**£**|
|Depreciation of tangible fixed assets||**-**|3,437|
|Net incoming resources||638,524|780,509|
|(Increase)/Decrease in debtors||299,314|(270,083)|
|Increase/ (Decrease) in creditors||(13,793)|19,356|
|||________|________|
|||924,045|533,219|
|||=======|=======|
|**(B) Analysis of changes in cash balances during the year**||||
|||**2025**|**2024**|
|||**£**|**£**|
|Cash at beginning of period||2,794,083|2,260,864|
|Cash at end of period||3,718,128|2,794,083|
|||________|________|
|Increase in cash||924,045|533,219|
|||=======|=======|



13 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1 Accounting policies** 

## **Company information** 

Cris Cancer Foundation is a private company limited by guarantee incorporated in England and Wales. The registered office is Quadrant House, Floor 6, 4 Thomas More Square, London, E1W 1YW. 

## **Accounting convention** 

These financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS  102) (effective 1 January 2019) - (Charities SORP - FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities Act 2011 and the requirements of the Companies Act 2006. 

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £. 

CRIS Cancer Foundation meets the definition of a public entity under FRS 102.  The financial statements have been prepared on the historical cost convention and the principal accounting policies adopted are set out below. 

## **Funds Structure** 

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by the donor. Unrestricted funds are funds which are used in accordance with the charitable objects at the discretion of the trustees. 

## **Incoming resources** 

Incoming resources are accrued and included in the SOFA when the charity is entitled to the income, the receipt can be quantified and is probable and deferred when they relate to future accounting periods.  Gift Aid receivable is included in income when there is a valid declaration from the donor and the donations has been received. 

The following policies apply to the following specific categories of income from fundraising events: 

## _Income from Annual Gala Dinner_ 

Ticket, auction and sponsorship income from the Annual Gala Dinner is disclosed under other trading activities and recognised when receivable. 

## _Income from personal challenge and other fundraising events_ 

Marathon, bike challenge and other fundraising income, which are in substance donations, are disclosed as donations when receivable. 

## **Investment income** 

Investment income represented by interest on monies held on deposit is included in SOFA when receivable by the charity. 

14 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



**CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1 Accounting policies (continued)** 

## **Resources expended and irrecoverable VAT** 

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. 

Irrecoverable VAT is charged against the category of resources expended for which it was incurred. 

## **Going concern** 

The accounts have been prepared under the going concern basis as the trustees are of the opinion that the ������������������������������including the annual Charity Gala Dinner, plus some reserve funds will cover minimal operational costs and enable the charity to meet its objectives of funding cancer research. 

## **Tangible fixed assets** 

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses.  Cost includes costs directly attributable to making the asset capable of operating as intended. 

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows: 

Fixtures and fittings 

20% on cost 

## **Investments** 

Programme-related investments are made to further to charitable purposes of the charity. They are held at cost less any provision for impairment. 

## **Financial instruments** 

����������������������������������������������������������������������������������������������������������� ������������������������������������������������������������������������������������ 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument. 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. 

## **Basic financial assets** 

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. 

15 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1 Accounting policies (continued)** 

## **Impairment of financial assets** 

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date. 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present ������������������������������������������������������������������������������������������������������������� loss is recognised in profit or loss. 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss. 

## **Derecognition of financial assets** 

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party. 

## **Classification of financial liabilities** 

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. 

## **Basic financial liabilities** 

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised. 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method. 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method. 

## **Derecognition of financial liabilities** 

����������������������������������������������������������������������������������������������� discharged or cancelled. 

## **Operating leases** 

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease. 

16 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



**CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **2 Employees** 

There was on average 4 employees in the period (2024: 5). 

## **Analysis of staff costs** 

||**2025**|**2024**|
|---|---|---|
||**£**|**£**|
|Salaries and Wages|148,523|160,397|
|Social Security Costs|8,017|11,277|
|Pensions|3,381|3,585|
||________|________|
||159,921|175,259|
||=======|=======|



## **Higher paid staff** 

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was 1 (2024: 1). 

No key management personnel are remunerated during the year (2024: 0). 

## **3 Income and endowments** 

|||||**2025**|**2024**|
|---|---|---|---|---|---|
||**Unrestricted**||**Restricted**|**Total**|**Total**|
|||**£**|**£**|**£**|**£**|
|3.1|**Donations and legacies**|||||
||Direct gifts from individuals and organisations|445,831|-|445,831|182,453|
||Events and other income|572,291|-|572,291|386,820|
|||________|________|________|________|
|||1,018,122|-|1,018,122|569,273|
|||=======|=======|=======|=======|
|3.2|**Other trading activities**|||||
||Annual Gala Dinner|2,772,478|-|2,772,478|2,807,184|
|||________|________|________|________|
|||2,772,478|-|2,772,478|2,807,184|
|||=======|=======|=======|=======|
|3.3|**Investments**|||||
||Bank interest|34,847|-|34,847|31,184|
|||=======|=======|=======|=======|



17 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



||**31 Dec**|**2025 Total**|**£**|||386,543||214,000|23,697|348,762|980,325|200,000|77,545|80,359|77,810|249,045|200,750|89,000|450|________|2,928,286|=======|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**Unrestricted funds**<br>**Restricted funds**|**Raising**<br>**Charitable**<br>**Raising**<br>**Charitable**|**Funds**<br>**activities**<br>**Sub-total**<br>**funds**<br>**activities**<br>**Sub-total**|**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**|||386,543<br>-<br>386,543<br>-<br>-<br>-||-<br>214,000<br>214,000<br>-<br>-<br>-|-<br>23,697<br>23,697<br>-<br>-<br>-|-<br>348,762<br>348,762<br>-<br>-<br>-|-<br>980,325<br>980,325<br>-<br>-<br>-|-<br>200,000<br>200,000<br>-<br>-<br>-|-<br>77,545<br>77,545<br>-<br>-<br>-|-<br>80,359<br>80,359<br>-<br>-<br>-|-<br>77,810<br>77,810<br>-<br>-<br>-|-<br>249,045<br>249,045<br>-<br>-<br>-|-<br>200,750<br>200,750<br>-<br>-<br>-|-<br>89,000<br>89,000<br>-<br>-<br>-|-<br>450<br>450<br>-<br>-<br>-|________<br>________<br>________<br>________<br>________<br>________|386,543<br>2,541,743            2,928,286<br>-<br>-<br>-|=======        =======           =======         ========         =======   =======|
|**Analysis of charitable expenditure**||||**Year ended 31 Dec 2025:**|**_Activities undertaken directly_**|Fundraising events|Donations made:|- CD22CAR vector|- Extension Project|- Institute of Cancer Research|- Fight Kids Cancer|- Oxford University Project|- Transfer to Cris Cancer Spain|- Transfer to Cris Cancer France|- Myeloma Dr Charlotte Pawlyn|- Centre for Trans. Immunotherapy|- Lung Cancer Vaccine- CRUK|- Prostate Cancer Foundation|- Other Investment Projects||||





||459|14,130|159,921|38,421|45,706|________|258,637|________|3,186,923|=======|
|---|---|---|---|---|---|---|---|---|---|---|
||-|-|-|-|-|________|-|________||=======|
||-|-|-|-|-|________|-|________||=======|
||-|-|-|-|-|________|-|________||=======|
||459|14,130|159,921|38,421|45,706|________|258,637|________|3,186,923|=======|
||312|9,600|56,831|26,103|31,080|________|123,926|________|2,665,669|=======|
||147|4,530|103,090|12,318|14,626|________|134,711|________|521,254|=======|
|**_Support costs_**|Accountancy|Audit Fees|Employee costs|General office costs|Professional costs||||||





|**4 Analysis of charitable expenditure (continued)**|**Unrestricted funds**<br>**Restricted funds**|**Raising**<br>**Charitable**<br>**Raising**<br>**Charitable**<br>**31 Dec**|**Funds**<br>**activities**<br>**Sub-total**<br>**funds**<br>**activities**<br>**Sub-total**<br>**2024 Total**|**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**|**Year ended 31 Dec 2024:**|**_Activities undertaken directly_**|Fundraising events<br>295,595<br>-              295,595<br>-<br>-<br>-<br>295,595|Donations made:|- CD22CAR vector<br>-<br>429,000<br>429,000<br>-<br>-<br>-<br>429,000|- Extension Project<br>-<br>53,030<br>53,030<br>-<br>-<br>-<br>53,030|- Institute of Cancer Research<br>-<br>511,634               511,634<br>-<br>-<br>-<br>511,634|- Fight Kids Cancer<br>-<br>851,119<br>851,119                          -<br>-<br>-<br>851,119|- Oxford University Project<br>-<br>100,000<br>100,000                          -<br>-<br>-<br>100,000|- Cancer Research UK<br>-<br>125,000<br>125,000                          -                        -                       -                    125,000|- Transfer to Cris Cancer Spain<br>-<br>5,089<br>5,089                          -                        -<br>-                        5,089|- Transfer to Cris Cancer France<br>-<br>7,713<br>7,713                          -<br>-<br>-                        7,713|________<br>________<br>________<br>________<br>________<br>________<br>________|295,595<br>2,082,585              2,378,180<br>-<br>-<br>-<br>2,378,180|=======        =======           =======         ========         =======   =======<br>=======|**_Support costs_**|Accountancy<br>586<br>1,238<br>1,824<br>-<br>-<br>-<br>1,824|Audit Fees<br>3,526<br>7,474<br>11,000<br>-<br>-<br>-<br>11,000|Employee costs<br>115,986<br>59,274<br>175,260<br>-<br>-<br>-<br>175,260|General office costs<br>15,732<br>33,341<br>49,073<br>-<br>-<br>-<br>49,073|Professional costs<br>2,674<br>5,683<br>8,357<br>-<br>-<br>-<br>8,357|Depreciation<br>1,102<br>2,336                    3,438<br>-<br>-<br>-<br>3,438|________<br>________<br>________<br>________<br>________<br>________<br>________|139,606<br>109,346<br>248,952<br>-<br>-<br>-<br>248,952|________<br>________<br>________<br>________<br>________<br>________<br>________|435,201          2,191,931           2,627,132                           -                        -                        -                2,627,132|=======<br>=======<br>=======<br>=======<br>=======<br>=======<br>=======<br>|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|





## **CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **5 Tangible fixed assets** 

|**5**|**Tangible fixed assets**||||
|---|---|---|---|---|
|||**Fixtures**|||
|||**&**||**Total**|
|||**Fittings**|||
|||**£**||**£**|
||**Cost or valuation:**||||
||At 1 January 2025|25,788||25,788|
||Additions||||
||At 31 December 2025|25,788||25,788|
||**Depreciation**:||||
||At 1 January 2025|25,788||25,788|
||Charge for the year||||
||At 31 December 2025|25,788||25,788|
||Net book value:||-|-|
||At 31 December 2025||||
||At 31 December 2024||-|-|
|**6**|**Programme-related investments (bond):**||||
|||**31 Dec 2025**|**31 Dec 2024**||
|||**£**||**£**|
||Investments|199,998||199,998|
|||=======||=======|



In previous year, the charity subscribed to 48,780 seed shares of Infinitopes Limited, a company registered in England and Wales. The charity made its investment in Infinitopes Limited in order to ������������������������������������������������������������and of developing new and better treatments for people with cancer. The charity will derive the benefit of this research from Infinitopes over the life of the investment. 

At the balance sheet date, the recoverable amount is deemed to be in excess of the original cost of the investment and as such, no triggers for impairment have been identified. 

## **7 Debtors: amounts falling due with one year:** 

||**31 Dec 2025 31 Dec 2024**|**31 Dec 2025 31 Dec 2024**|
|---|---|---|
||**£**|**£**|
|Trade debtors|512,524|779,737|
|Prepayments|-|32,101|
|Other debtors|4,500|4,500|
||________|________|
||517,024|816,338|
||=======|=======|



21 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



## **CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **8 Other creditors: amounts falling due within one year** 

|||**31 Dec 2025**|**31 Dec 2024**|
|---|---|---|---|
|||**£**|**£**|
||Other creditors and accruals|34,637|48,430|
|||=======|=======|
|**9**|**Financial instruments**|**31 Dec 2025**|**31 Dec 2024**|
|||**£**|**£**|
||Carrying amount of financial assets:|||
||Investments|199,998|199,998|
||Debtors|512,524|779,737|
||Prepayments|-|32,101|
||Other debtors|4,500|4,500|
|||________|________|
|||717,022|1,016,336|
||Carrying amount of financial liabilities:|||
||Other creditors|(34,637)|(48,430)|
|||________|________|
|||682,385|967,906|
|||=======|<br>=======|



**10 Operating lease commitments** At the reporting end date, the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows: 

|||||**31 Dec 2025**|**31 Dec 2024**|
|---|---|---|---|---|---|
|||||**£**|**£**|
||Within 1 year|||25,200|25,200|
||2 � 5 years|||12,600|37,800|
|||||________|________|
|||||37,800|63,000|
|||||=======|=======|
|**11**|**Analysis of charitable funds**|||||
|||**Balance at**|**Incoming**|**Resources**|**Balance at**|
|||**1 Jan 2025**|**resources**|**expended**|**31 Dec 2025**|
|||**£**|**£**|**£**|**£**|
||Unrestricted funds:|||||
||General Funds|3,761,989|3,825,447|3,186,923|4,400,513|
|||________|________|________|________|
|||3,761,989|3,825,447|3,186,923|4,400,513|
||Restricted funds<br>|-|-|-|-|
|||________|________|________|<br>________|
||Total|3,761,989|3,825,447|3,186,923|4,400,513|
|||=======|=======|=======|=======|



22 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC 



**CRIS CANCER FOUNDATION** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **12 Analysis of net assets between funds** 

||**Unrestricted**|**Restricted**||**Total**||**Total**|
|---|---|---|---|---|---|---|
||**funds**|**funds**|**31 Dec 2025**||**31 Dec 2024**||
||**£**|**£**||**£**||**£**|
|Fixed assets|-|-||-||-|
|Investments|199,998|-||199,998||199,998|
|Debtors|517,024|-||517,024||816,338|
|Bank|3,718,128|-||3,718,128||2,794,083|
|Creditors|(34,637)|-||(34,637)||(48,430)|
||________|________||________||________|
||4,400,513|-||4,400,513||3,761,989|
||=======|=======||=======||=======|



## **13 ��������������������** 

No trustee or any person connected with a trustee has received or is due to receive any remuneration or ������������������������������������������������������������������������ 

## **14 Related party transactions** 

CRIS made donations of £77,545 (2024: £5,089) to Fundacion CRIS de Investigacion para Vencer el Cancer, a charitable organisation registered in Spain and related to CRIS by virtue of common trustees, Lola Manterola and Diego Megia. 

CRIS also made a donation of £80,359 (2024: £7,713) to CRIS Cancer France, a charitable organisation which is related to CRIS by virtue of common trustees, Lola Manterola and Diego Megia. 

During the period, the trustees made donations to CRIS totalling £352,348 (2024: £465,325). 

## **15 Taxation** 

As a charity, the Foundation is exempt from UK corporation tax to the extent that its income is applied to its charitable objects.  No liability arose in the year. 

## **16 Capital commitments** 

At the year end, the charity is committed to make donation of £2,027,150 (2024: £1,874,075) to ICR and other Cancer projects through deeds of gifts. 

23 

RSign Envelope ID: ENV04920743-9654-FAFB-2260-BFAA  09/07/2026 16:38 PM UTC